Phathom Pharmaceuticals Inc. Receives FDA Exclusivity Extension for Voquezna

Phathom Pharmaceuticals Inc., a biopharmaceutical company specializing in gastrointestinal (GI) treatments, has recently received a significant boost following the U.S. Food and Drug Administration’s (FDA) decision to grant a 10-year regulatory exclusivity extension for its drug Voquezna (vonoprazan). This decision, announced on June 6, 2025, ensures that Voquezna will be protected from generic competition until May 3, 2032.

The exclusivity extension covers multiple approved indications, including gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) treatment, significantly strengthening Phathom’s intellectual property position. This development has been met with positive reactions from the financial community, with analysts from Guggenheim and Stifel reaffirming their “Buy” ratings for Phathom’s stock.

Following the announcement, Phathom’s stock experienced a dramatic surge, with shares soaring by approximately 125%, as reported by Seeking Alpha. This surge reflects investor confidence in the company’s strengthened market position and future revenue potential. The stock’s close price on June 5, 2025, was $8.92, with a 52-week high of $19.71 and a low of $2.21.

The market capitalization of Phathom Pharmaceuticals stands at $327.43 million, with a negative price-to-earnings ratio of -0.894391, indicating the company’s current financial challenges despite the positive news. The company, listed on the Nasdaq stock exchange, continues to focus on developing and commercializing treatments for GI diseases and disorders.

This regulatory milestone is expected to provide Phathom with extended market protection, allowing the company to capitalize on its innovative treatments and potentially improve its financial performance in the coming years. For more information on Phathom Pharmaceuticals and its activities, interested parties can visit their website at www.phathompharma.com .